Deciphering key parameters enhancing lentiviral vector producer cells yields: Vector components copy number and expression.

IF 4.7 2区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Molecular Therapy-Methods & Clinical Development Pub Date : 2025-02-10 eCollection Date: 2025-03-13 DOI:10.1016/j.omtm.2025.101431
Ana S Formas-Oliveira, Mariana Valentim Ferreira, Ana Sofia Coroadinha
{"title":"Deciphering key parameters enhancing lentiviral vector producer cells yields: Vector components copy number and expression.","authors":"Ana S Formas-Oliveira, Mariana Valentim Ferreira, Ana Sofia Coroadinha","doi":"10.1016/j.omtm.2025.101431","DOIUrl":null,"url":null,"abstract":"<p><p>The use of lentiviral vectors (LVs) in gene therapy is expanding, demanding high-quality viral preparations. Producer cell lines for LV production offer robust manufacturing platforms. However, their development is still progressing and more knowledge on the impact of vector components expression levels on vector yields and quality is essential. This work studies the impact of vector cassette expression and stability on vector titer and quality, identifying key parameters in cell line development. Ten heterogeneous LV stable producer clones established through random cassette integration were characterized. The <i>gag-pol</i> and <i>rev</i> cassettes, expressed under the control of constitutive promoters, showed robust expression generating titers of 10<sup>9</sup> physical particles (P.P.s)/mL. However, <i>Pol</i> and reverse transcriptase expressions were shown to be better indicators of potential functional titers. Envelope and transfer vector expression levels were key to attaining high functional particles yields. The stability analysis of two top clones and their <i>trans</i>-complementation with each genetic cassette further supported this conclusion. The producer LV clones expressed constitutively the 4070A envelope, but the overexpression of the VSV-G envelope increased 30-fold the titer supporting the envelope as key determinant in LV quality. This work further elucidates bottlenecks in LV producer cell line development providing insights for their optimization.</p>","PeriodicalId":54333,"journal":{"name":"Molecular Therapy-Methods & Clinical Development","volume":"33 1","pages":"101431"},"PeriodicalIF":4.7000,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925171/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy-Methods & Clinical Development","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omtm.2025.101431","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/13 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

The use of lentiviral vectors (LVs) in gene therapy is expanding, demanding high-quality viral preparations. Producer cell lines for LV production offer robust manufacturing platforms. However, their development is still progressing and more knowledge on the impact of vector components expression levels on vector yields and quality is essential. This work studies the impact of vector cassette expression and stability on vector titer and quality, identifying key parameters in cell line development. Ten heterogeneous LV stable producer clones established through random cassette integration were characterized. The gag-pol and rev cassettes, expressed under the control of constitutive promoters, showed robust expression generating titers of 109 physical particles (P.P.s)/mL. However, Pol and reverse transcriptase expressions were shown to be better indicators of potential functional titers. Envelope and transfer vector expression levels were key to attaining high functional particles yields. The stability analysis of two top clones and their trans-complementation with each genetic cassette further supported this conclusion. The producer LV clones expressed constitutively the 4070A envelope, but the overexpression of the VSV-G envelope increased 30-fold the titer supporting the envelope as key determinant in LV quality. This work further elucidates bottlenecks in LV producer cell line development providing insights for their optimization.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
解密提高慢病毒载体生产细胞产量的关键参数:载体成分的拷贝数和表达量
慢病毒载体(LVs)在基因治疗中的应用正在扩大,这就需要高质量的病毒制剂。低压生产的生产者细胞系提供了强大的制造平台。然而,它们的发展仍在继续,更多的了解载体成分表达水平对载体产量和质量的影响是必不可少的。本工作研究了载体盒表达和稳定性对载体滴度和质量的影响,确定了细胞系发育的关键参数。通过随机盒式整合建立了10个异质LV稳定生产者无性系。在组成启动子控制下表达的gag-pol和rev磁带显示出稳健的表达,产生的滴度为109物理粒子(P.P.s)/mL。然而,Pol和逆转录酶的表达被证明是潜在功能滴度的更好指标。包膜和转移载体的表达水平是获得高功能颗粒产量的关键。两个顶端无性系的稳定性分析及其与各遗传盒的反式互补进一步支持了这一结论。生产者LV克隆基本表达4070A包膜,但VSV-G包膜的过表达增加了30倍,支持包膜作为LV质量的关键决定因素。这项工作进一步阐明了LV生产者细胞系发展的瓶颈,为其优化提供了见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Molecular Therapy-Methods & Clinical Development
Molecular Therapy-Methods & Clinical Development Biochemistry, Genetics and Molecular Biology-Molecular Biology
CiteScore
9.90
自引率
4.30%
发文量
163
审稿时长
12 weeks
期刊介绍: The aim of Molecular Therapy—Methods & Clinical Development is to build upon the success of Molecular Therapy in publishing important peer-reviewed methods and procedures, as well as translational advances in the broad array of fields under the molecular therapy umbrella. Topics of particular interest within the journal''s scope include: Gene vector engineering and production, Methods for targeted genome editing and engineering, Methods and technology development for cell reprogramming and directed differentiation of pluripotent cells, Methods for gene and cell vector delivery, Development of biomaterials and nanoparticles for applications in gene and cell therapy and regenerative medicine, Analysis of gene and cell vector biodistribution and tracking, Pharmacology/toxicology studies of new and next-generation vectors, Methods for cell isolation, engineering, culture, expansion, and transplantation, Cell processing, storage, and banking for therapeutic application, Preclinical and QC/QA assay development, Translational and clinical scale-up and Good Manufacturing procedures and process development, Clinical protocol development, Computational and bioinformatic methods for analysis, modeling, or visualization of biological data, Negotiating the regulatory approval process and obtaining such approval for clinical trials.
期刊最新文献
When pullulanase needs a little push: MyoAAV capsids enhance gene therapy for GSD IIIa. Why regulatory T cells love lactic acid. Rapid kinetics of AAV8 delivery of Vglut3 and hearing rescue shown day-by-day via matched IHC and ABR. Toward CAR-B cells for HIV-1 therapy. The Advanced Therapies model of Lund an integrated approach to accelerate access for many patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1